Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae

Livermore, David M.; Mushtaq, Shazad; Nguyễn, Tùng Lâm; Warner, Marina

doi:10.1016/j.ijantimicag.2010.11.028

Cited by 20 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Experiments with E. coli transconjugants showed that mecillinam MICs rose to 8mg/L when CTX-M-15 or -3 were present but only to 0.25-0.5mg/L with CTX-M-9 or -14. Combination with clavulanate reduced all mecillinam MICs for ESBL producers (except SHV-4) to <=4mg/L at high inocula and <=2mg/L with usual light inocula 389 . In another study of combination with clavulanate 418 68 .…”

Section: Saprophyticusmentioning

confidence: 95%

“…Mecillinam is inactive against Enterobacteriaceae with KPC enzymes but some published data suggest in vitro activity against isolates with OXA-48-like enzymes 68,389 and even some with NDM-1 enzymes, as reflected in an MIC50 of 4mg/L for NDM carbapenemase-producing E. coli 420 although this low value is disputed by others (D.M.…”

Section: Saprophyticusmentioning

confidence: 98%

“…Cefixime could be used in combination with co-amoxiclav against ESBLproducing Enterobacteriaceae as supported by in vitro data388 . Data from transconjugant E. coli further suggests cefixime plus clavulanate is effective against strains producing CTX-M-15 enzyme which has higher cefixime MICs than strains producing CTX-M-9 enzyme389 . Other oral cephalosporins including cefdinir, ceftibuten, and cefpodoxime also showed synergy with clavulanate whereas sulbactam was less effective as a potentiator.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†

Hawkey

Warren

Livermore

et al. 2018

Journal of Antimicrobial Chemotherapy

273

201

View full text Add to dashboard Cite

The Working Party makes more than 100 tabulated recommendations in antimicrobial prescribing for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) and suggest further research, and algorithms for hospital and community antimicrobial usage in urinary infection. The international definition of MDR is complex, unsatisfactory and hinders the setting and monitoring of improvement programmes. We give a new definition of multiresistance. The background information on the mechanisms, global spread and UK prevalence of antibiotic prescribing and resistance has been systematically reviewed. The treatment options available in hospitals using intravenous antibiotics and in primary care using oral agents have been reviewed, ending with a consideration of antibiotic stewardship and recommendations. The guidance has been derived from current peer-reviewed publications and expert opinion with open consultation. Methods for systematic review were NICE compliant and in accordance with the SIGN 50 Handbook; critical appraisal was applied using AGREE II. Published guidelines were used as part of the evidence base and to support expert consensus. The guidance includes recommendations for stakeholders (including prescribers) and antibiotic-specific recommendations. The clinical efficacy of different agents is critically reviewed. We found there are very few good-quality comparative randomized clinical trials to support treatment regimens, particularly for licensed older agents. Susceptibility testing of MDR GNB causing infection to guide treatment needs critical enhancements. Meropenem- or imipenem-resistant Enterobacteriaceae should have their carbapenem MICs tested urgently, and any carbapenemase class should be identified: mandatory reporting of these isolates from all anatomical sites and specimens would improve risk assessments. Broth microdilution methods should be adopted for colistin susceptibility testing. Antimicrobial stewardship programmes should be instituted in all care settings, based on resistance rates and audit of compliance with guidelines, but should be augmented by improved surveillance of outcome in Gram-negative bacteraemia, and feedback to prescribers. Local and national surveillance of antibiotic use, resistance and outcomes should be supported and antibiotic prescribing guidelines should be informed by these data. The diagnosis and treatment of both presumptive and confirmed cases of infection by GNB should be improved. This guidance, with infection control to arrest increases in MDR, should be used to improve the outcome of infections with such strains. Anticipated users include medical, scientific, nursing, antimicrobial pharmacy and paramedical staff where they can be adapted for local use.

show abstract

Section: Saprophyticusmentioning

confidence: 95%

Section: Saprophyticusmentioning

confidence: 98%

mentioning

confidence: 99%

See 1 more Smart Citation

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†

Hawkey

Warren

Livermore

et al. 2018

Journal of Antimicrobial Chemotherapy

273

201

View full text Add to dashboard Cite

show abstract

“…To investigate alternative treatment strategies to overcome the ESBL problem is of high interest. 17 This study showed that sulbactam significantly potentiates ceftazidime and cefepime against ESBL-positive E.coli and so deserves further investigation as an alternative strategy of empirical treatment in certain situations, including sepsis of urinary origin and febrile neutropenia where E.coli is a concern. Dissemination of the ST131 clone with CTX-M-type ESBLs does not affect the potency of these combinations.…”

Section: Discussionmentioning

confidence: 81%

In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli

Kolaylı¹

2011

JMID

View full text Add to dashboard Cite

Objectives: The primary aim of this study was to determine the activities of ceftazidime and cefepime combined to sulbactam against class A extended-spectrum β lactamases (ESBLs). Materials and methods: Eight university hospitals participated to the study by submitting isolates those were recovered during a six-month period in 2010 from various clinical materials. Sulbactam was tested in two fixed concentrations of 4 mg/l and 8 mg/l. Isolates showing a fourfold or more decrease in the MIC of an oxyimino-cephalosporin with sulbactam were defined as ESBL producers. Isolates were screened for CTX-M group 1 extended-spectrum β lactamases by PCR. Results: A total of 149 ESBL-positive E.coli were studied. Isolates were uniformly susceptible to carbapenems and highly resistant to ciprofloxacin. According to CLSI breakpoints, 28% (42/149) of isolates were susceptible to ceftazidime and 32% (47/149) to cefepime. With 4 mg/L and 8 mg/L sulbactam supplement, ceftazidime susceptibility rose to 69% (103/149) and 88% (131/149), while cefepime susceptibility rose to 86 % (128/149) and 95% (141/149), respectively. PCR screening revealed that 63% (94/149) of the isolates were positive for blaCTX-M and 38% (36/94) of these were on the O25b-ST131 clone. Conclusion: Ceftazidime plus sulbactam and cefepime plus sulbactam showed remarkable activity against ESBL-positive E.coli.

show abstract

“…The bacteria are excreted through feces and are transmitted by ingestion of contaminated food and water [1]. To reduce the severity of the clinical course of illness and the duration of fecal excretion of bacteria, the WHO recommends ciprofloxacin as the first-line treatment for shigellosis [2, 3]. Ampicillin and trimethoprim-sulfamethoxazole are no longer sufficiently effective due to increases in the bacterial resistance to these drugs [4].…”

Section: Introductionmentioning

confidence: 99%

CTX-M-55-Type Extended-Spectrum β-lactamase- Producing Shigella sonnei Isolated from a Korean Patient Who Had Travelled to China

et al. 2013

View full text Add to dashboard Cite

We report a case of CTX-M-55-type extended-spectrum β-lactamase (ESBL)-producing Shigella sonnei infection in a 27-year-old Korean woman who had traveled to China. The patient was admitted to the hospital due to abdominal pain, watery diarrhea, and fever (39.3℃). S. sonnei was isolated from her stool specimens, and the pathogen was found to be resistant to cefotaxime due to CTX-M-55-type ESBL. Insertion sequence (IS)Ecp1 was found upstream of the blaCTX-M-55 gene. The blaCTX-M-55 gene was transferred from the S. sonnei isolate to an Escherichia coli J53 recipient by conjugation. Pulsed-field gel electrophoresis and Southern blotting revealed that the blaCTX-M-55 gene was located on a plasmid of approximately 130 kb.

show abstract

Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae

Cited by 20 publications

References 21 publications

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†

In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli

CTX-M-55-Type Extended-Spectrum β-lactamase- Producing Shigella sonnei Isolated from a Korean Patient Who Had Travelled to China

Contact Info

Product

Resources

About